Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platinum-Pemetrexed-Atezolizumab (± Bevacizumab) in EGFR/ALK/ROS1 NSCLC After Targeted Therapy
2024-516201-23-00Phase 2Completed
- Sponsor
- Centre François Baclesse
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, pemetrexed, cisplatin, carboplatin and bevacizumab in Non-small cell lung cancer (NS-NSCLC) and bronchial carcinoma, sponsored by Centre François Baclesse. Primary endpoint: Objective response rate (RECIST v1.1, central review) after induction. Started Nov 2024; status: completed.
02
Drugs
atezolizumabpemetrexedcisplatincarboplatinbevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on 2024-516201-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516201-23-00.